Skip to main content

Research Repository

Advanced Search

Outputs (29)

Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation (2023)
Preprint / Working Paper
Abhishek, A., Grainge, M. J., Card, T., Williams, H. C., Taal, M. W., Aithal, G. P., Fox, C. P., Mallen, C. D., Stevenson, M. D., Nakafero, G., & Riley, R. D. Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation

Background Sulfasalazine induced cytopenia, nephrotoxicity, and hepatotoxicity is uncommon during long-term treatment. Some guidelines recommend three monthly monitoring blood-tests indefinitely while others recommend stopping monitoring after one ye... Read More about Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation.

Next-generation sequencing of pancreatic cyst wall specimens obtained using micro-forceps for improving diagnostic accuracy (2023)
Journal Article
Astbury, S., Baskar, A., Grove, J. I., Kaye, P., Aravinthan, A. D., James, M., Clarke, C., Aithal, G. P., & Venkatachalapathy, S. V. (2023). Next-generation sequencing of pancreatic cyst wall specimens obtained using micro-forceps for improving diagnostic accuracy. Endoscopy International Open, 11(10), E983-E991. https://doi.org/10.1055/a-2163-8805

Background and study aims: Pancreatic cysts are common incidental findings, with an estimated prevalence of 13-15% in imaging done for other reasons. Diagnosis often relies on collection of cyst fluid, but tissue sampling using micro-forceps may allo... Read More about Next-generation sequencing of pancreatic cyst wall specimens obtained using micro-forceps for improving diagnostic accuracy.

Liver investigation: Testing marker utility in steatohepatitis (LITMUS): Assessment & validation of imaging modality performance across the NAFLD spectrum in a prospectively recruited cohort study (the LITMUS imaging study): Study protocol (2023)
Journal Article
Pavlides, M., Mózes, F. E., Akhtar, S., Wonders, K., Cobbold, J., Tunnicliffe, E. M., Allison, M., Godfrey, E. M., Aithal, G. P., Francis, S., Romero-Gomez, M., Castell, J., Fernandez-Lizaranzu, I., Aller, R., Sigüenza González, R., Agustin, S., Pericàs, J. M., Boursier, J., Aube, C., Ratziu, V., …Harrison, S. (2023). Liver investigation: Testing marker utility in steatohepatitis (LITMUS): Assessment & validation of imaging modality performance across the NAFLD spectrum in a prospectively recruited cohort study (the LITMUS imaging study): Study protocol. Contemporary Clinical Trials, 134, Article 107352. https://doi.org/10.1016/j.cct.2023.107352

Non-alcoholic fatty liver disease (NAFLD) is the liver manifestation of the metabolic syndrome with global prevalence reaching epidemic levels. Despite the high disease burden in the population only a small proportion of those with NAFLD will develop... Read More about Liver investigation: Testing marker utility in steatohepatitis (LITMUS): Assessment & validation of imaging modality performance across the NAFLD spectrum in a prospectively recruited cohort study (the LITMUS imaging study): Study protocol.

Study design for development of novel safety biomarkers of drug-induced liver injury by the translational safety biomarker pipeline (TransBioLine) consortium: a study protocol for a nested case–control study (2023)
Journal Article
Grove, J. I., Stephens, C., Lucena, M. I., Andrade, R. J., Weber, S., Gerbes, A., Bjornsson, E. S., Stirnimann, G., Daly, A. K., Hackl, M., Khamina-Kotisch, K., Marin, J. J. G., Monte, M. J., Paciga, S. A., Lingaya, M., Forootan, S. S., Goldring, C. E. P., Poetz, O., Lombaard, R., Stege, A., …on behalf of the TransBioLine consortium. (2023). Study design for development of novel safety biomarkers of drug-induced liver injury by the translational safety biomarker pipeline (TransBioLine) consortium: a study protocol for a nested case–control study. Diagnostic and Prognostic Research, 7, Article 18. https://doi.org/10.1186/s41512-023-00155-z

A lack of biomarkers that detect drug-induced liver injury (DILI) accurately continues to hinder early- and late-stage drug development and remains a challenge in clinical practice. The Innovative Medicines Initiative’s TransBioLine consortium compri... Read More about Study design for development of novel safety biomarkers of drug-induced liver injury by the translational safety biomarker pipeline (TransBioLine) consortium: a study protocol for a nested case–control study.

Incidence, risk factors and outcomes of checkpoint inhibitor-induced liver injury: A 10-year real-world retrospective cohort study (2023)
Journal Article
Atallah, E., Welsh, S. J., O'Carrigan, B., Oshaughnessy, A., Dolapo, I., Kerr, A. S., Kucharczak, J., Lee, C., Crooks, C., Hicks, A., Chimakurthi, C. R., Rao, A., Franks, H., Patel, P. M., & Aithal, G. P. (2023). Incidence, risk factors and outcomes of checkpoint inhibitor-induced liver injury: A 10-year real-world retrospective cohort study. JHEP Reports, 5(10), Article 100851. https://doi.org/10.1016/j.jhepr.2023.100851

Background & Aims: Checkpoint inhibitors (CPI) account for increasing numbers of drug-induced liver injury (DILI) cases. We aimed to determine the incidence rate and risk factors associated with checkpoint inhibitor-induced liver injury (ChILI). Meth... Read More about Incidence, risk factors and outcomes of checkpoint inhibitor-induced liver injury: A 10-year real-world retrospective cohort study.

Application and Extension of the Alcohol Recovery Narratives Conceptual Framework (2023)
Journal Article
Subhani, M., Talat, U., Knight, H., Morling, J. R., Jones, K. A., Aithal, G. P., Ryder, S. D., & Rennick-Egglestone, S. (2023). Application and Extension of the Alcohol Recovery Narratives Conceptual Framework. Qualitative Health Research, 33(13), 1203-1217. https://doi.org/10.1177/10497323231197384

Recovery narratives are personal stories of health problems and recovery. A systematic review proposed a conceptual framework characterising alcohol misuse recovery narratives, consisting of eight principal dimensions, each with types and subtypes. T... Read More about Application and Extension of the Alcohol Recovery Narratives Conceptual Framework.

Biomarkers of Type IV Collagen Turnover Reflect Disease Activity in Patients with Early-Stage Non-Alcoholic Fatty Liver (NAFL) (2023)
Journal Article
Lønsmann, I., Grove, J. I., Haider, A., Kaye, P., Karsdal, M. A., Leeming, D. J., & Aithal, G. P. (2023). Biomarkers of Type IV Collagen Turnover Reflect Disease Activity in Patients with Early-Stage Non-Alcoholic Fatty Liver (NAFL). Biology, 12(8), Article 1087. https://doi.org/10.3390/biology12081087

Background: Identification of progressive liver disease necessitates the finding of novel non-invasive methods to identify and monitor patients in need of early intervention. Investigating patients with early-liver injury may help identify unique bio... Read More about Biomarkers of Type IV Collagen Turnover Reflect Disease Activity in Patients with Early-Stage Non-Alcoholic Fatty Liver (NAFL).

Patients with Naproxen-Induced Liver Injury Display T-cell Memory Responses Towards an Oxidative (S)-O-Desmethyl Naproxen Metabolite but not the Acyl Glucuronide (2023)
Journal Article
Thomson, P., Fragkas, N., Kafu, L., Aithal, G., Lucena, M., Terracciano, L., Meng, X., Pirmohamed, M., Brees, D., Kullak-Ublick, G., Odermatt, A., Hammond, T., Kammuller, M., & Naisbitt, D. (2024). Patients with Naproxen-Induced Liver Injury Display T-cell Memory Responses Towards an Oxidative (S)-O-Desmethyl Naproxen Metabolite but not the Acyl Glucuronide. Allergy, 79(1), 200-214. https://doi.org/10.1111/all.15830

Background: Exposure to non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen (IBU) and naproxen (NAP) is associated with idiosyncratic drug-induced liver injury (DILI). Carboxylate bioactivation into reactive metabolites (e.g. acyl glucur... Read More about Patients with Naproxen-Induced Liver Injury Display T-cell Memory Responses Towards an Oxidative (S)-O-Desmethyl Naproxen Metabolite but not the Acyl Glucuronide.